The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
about
Immunotherapy strategies for multiple myeloma: the present and the futureTime-dependent endpoints as predictors of overall survival in multiple myelomaLongitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaTreatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.On the safety of low-dose dasatinib in comorbid and non-comorbid patients: what is real-life? (Reply).
P2860
Q27021939-20CFA0AC-7D44-4D65-9608-FCA1375309A4Q30538040-043DA993-1C65-4242-9A5E-ECFF9B719455Q34399099-FD4C97E9-8277-4638-942E-7DE655C41A76Q36012111-28BB94E0-B659-44F3-8AEE-AC4494D3AAAAQ37949201-D15F169F-8AE1-4E18-B74B-E59D4EF6820AQ38707841-37045A08-070E-478B-9D94-FA8600EC9C30Q46974306-88F9110D-D471-4BBC-B9E6-9C4C132D1459
P2860
The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The incidence of pleural and p ...... satinib at low doses. (Reply).
@en
The incidence of pleural and p ...... eiving dasatinib at low doses.
@nl
type
label
The incidence of pleural and p ...... satinib at low doses. (Reply).
@en
The incidence of pleural and p ...... eiving dasatinib at low doses.
@nl
prefLabel
The incidence of pleural and p ...... satinib at low doses. (Reply).
@en
The incidence of pleural and p ...... eiving dasatinib at low doses.
@nl
P2093
P2860
P1433
P1476
The incidence of pleural and p ...... asatinib at low doses. (Reply)
@en
P2093
Enrica Morra
Enrico Montefusco
Giuseppe Visani
Massimo Breccia
P2860
P304
e23-4; author reply e25
P356
10.3324/HAEMATOL.2011.041319
P577
2011-04-01T00:00:00Z